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We read with interest the article by
We˛drychowicz et al. (1). Maturity-onset
diabetes of the young (MODY) is a het-
erogeneous group of monogenic forms
of diabetes. Differential diagnosis with
common forms such as type 1 and type 2
diabetes frequently poses a challenge to
clinicians, especially in MODY forms
caused by transcription factors. Glucoki-
nase (GCK)-MODY stands out in this re-
gard for displaying a rather constant
phenotype (2).
We agree with the authors that the
incidental association of obesity with
GCK mutations can act as a diagnostic
confounder. Moreover, coexistence of
clinical features of both type 1 and
type 2 diabetes is well described in the
form of double diabetes. Individuals
with type 1 diabetes can show a broad
range of cardiovascular risk factors, such
as dyslipidemia and hypertension, cor-
related with different degrees of glyce-
mic control (3). Nevertheless, we feel
some key elements to establish a causal
role for both a GCKmutation and persis-
tent islet autoimmunity are lacking from
this patient description.
GCK-MODY phenotype is ﬁrmly es-
tablished as a syndrome of early-onset
mild fasting hyperglycemia, frequently
in the nondiabetic or prediabetic range
(2). Glucose excursions after an oral glu-
cose challenge are closer to normal in-
dividuals than other types of diabetes.
Therefore, the absence of available fast-
ing glucose values for the patient and
the relatively high 2-h value partially
undermine the clinical hypothesis of
GCK-MODY. Moreover, a detailed de-
scription of base and amino acid substi-
tutions in the mutation would be
necessary, as there is the possibility
of a single nucleotide polymorphism. A
previous description of functional stud-
ies of the mutation would also be help-
ful to establish the GCK mutation’s
causal role in this complex case. A
more detailed description of clinical
characteristics of other relatives with
diabetes would be likewise necessary
as it could simply reﬂect a pattern typ-
ical of type 2 diabetes, compatible with
the ﬁnding of hyperinsulinemia and dys-
lipidemia. Furthermore, risperidone use
also shows a frequent association with
hyperglycemia, obesity, and dyslipid-
emia (4).
Islet autoantibodies may be present
in asymptomatic individuals, mainly in
relatives of patients with type 1 diabe-
tes. Prospective studies demonstrated
that appearance of multiple antibodies
is usually sequential rather than simul-
taneous and that the number (two or
more) of positive antibodies is a strong
predictor of progression to overt type 1
diabetes. Patients with low titers of a sin-
gle antibody may ﬂuctuate, transiently
showing negative values. However,
remission of all antibodies in a patient
with three different types of antibodies
present is virtually unheard of, thus rais-
ing the possibility of methodological
problems (5). This could render transient
autoimmunity unlikely at this moment of
the patient’s history.
In conclusion, this can be regarded
as a complex case of diabetes in the
young. Previous obesity, hereditary pre-
disposition to type 2 diabetes, and anti-
psychotic use may possibly converge in
its pathogenesis. However, some diag-
nostic caveats should be solved and in-
terpreted with caution, along with a
longer clinical follow-up, before a diag-
nosis of triple diabetes is conﬁrmed.
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